| E |
|
Early control of the first stage of the response to LD100 E. coli may optimize the therapeutic effect of activated protein C
|
| Taylor Jr F. |
| |
|
Early developments of the post-thrombotic syndrome in overweight and obese patients
|
| Ageno W., Dentali F., Steidl L., Squizzato A., Mera V., Marchesi C., Manfredi E., Venco A. |
| |
|
Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VII
|
| Mahé I., Drouet L., Bertola J. P., Mazoyer E., Simoneau G., Caulin C., Bergmann J. F. |
| |
|
Early therapeutic splenectomy may reduce morbidity and management costs in selected resistant or relapsing cases of TTP/HUS
|
| Zomas A., Gigantes S., Vasiloglou G., Fragia K., Marinakis TH., Gortzolidis G., Leivada A., Mihalis E., Galanopoulos A., Skandalis A., Anagnostopoulos N. I. |
| |
|
Economic evaluation in hemophilia care
|
| Bohn R. |
| |
|
Economic evaluation of anti-D immunoglobulin in the treatment of immune thrombocytopenic purpura in adults in the United Kingdom
|
| Sclar D., Skaer T. L., Evans M. A., Robison L. M., Chung K. C., Poulios N. S. |
| |
|
Economic modeling of full-length anti-hemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM), vs. B-domain deleted rFVIII (BDDrFVIII) in previously treated patients (PTPs) with hemophilia A
|
| Sclar D., Skaer T. L., Evans M. A., Robison L. M., Ewenstein B., Yi S. E., Spotts G., Sun L., Poulios N. |
| |
|
EF6265: a new synthetic, potent and selective plasma CPB/TAFIa inhibitor
|
| Yoshioka S., Suzuki K., Muto Y., Fushihara K., Kanemoto K., Sato E., Ishii H. |
| |
|
Effect of in vivo thrombin inhibition on bFGF-induced angiogenesis in a murine angiogenic model
|
| Rosey G., Mouquet F., Susen S., Corseaux D., Zawadzki C., Vercamer C., Van Belle E., Jude B. |
| |
|
Effect of a nitric oxide donor on platelet reactivity and spontaneous thrombolysis in patients with chronic renal failure
|
| Ikaguri H., Yamashita T., Naemura A., Ishii H., Yamamoto J. |
| |
|
Effect of a RNA-thrombin aptamer on thrombin inhibition by antithrombin, heparin cofactor II and protein C inhibitor
|
| Fortenberry Y., Ly L., Jeter M. L., Rusconi C. P., Sullenger B. A., Whinna H. C., Church F. C. |
| |
|
Effect of ADP P2Y12 receptor inhibition on thrombosis and bleeding measured using guinea pigs
|
| Hashimoto M., Naemura A., Seki J., Yamamoto J. |
| |
|
Effect of age on the incidence of venous thromboembolism after surgery
|
| White R., Gage B. F., Zhou H. |
| |
|
Effect of angiotensin II and their metabolites on hemostasis in rats
|
| Mogielnicki A., Chabielska E., Buczko W. |
| |
|
Effect of angiotensin II on tissue factor expression in human peripheral blood monocytes
|
| He S. L., He M. X., He X. F., Wen Z. B. |
| |
|
Effect of anti-coagulant and anti-platelet agents on LPS-induced alteration of whole blood fluidity
|
| Haruhiko K. |
| |
|
Effect of anticoagulants with various modes of action on thrombin generation in plasma of mice with targeted Arg47-to-Cys mutation of the heparin-binding domain of antithrombin
|
| Herault J.-P., Dewerchin M., Petitou M., Bono F., Carmeliet P., Herbert J.M. |
| |
|
Effect of antiphospholipid antibodies in the activation of the contact complex: importance in the obstetric complications of the antipospholipid syndrome
|
| Reverter J. C., Lázaro I., Tassies D., Carmona F., Jorda M., Espinosa G., Ulloa W., Monteagudo J., Díaz-Ricart M., Escolar G., Font J., Balasch J., Ordinas A. |
| |
|
Effect of antithrombin on lipopolysaccharide stimulated gene expression by human umbilical vein endothelial cells
|
| Morrison M., Kalina U., Gray E. |
| |
|
Effect of apolipoprotein(a) on plasminogen activation-induced apoptosis of vascular smooth muscle cells
|
| Ho-Tin-Noé B., Meilhac O., Loyau S., Anglés-Cano E. |
| |
|
Effect of bezafibrate on plasma homocysteine in men with lower extremity arterial disease
|
| Maccallum P. K., Cooper J. A., Rumley A., Lowe G. D. O., Meade T. W. |
| |
|
Effect of cellular and receptor activation on the extent of integrin alphaIIb beta3 internalization
|
| Schober J. M., Lam S. C. T., Wencel-Drake J. D. |
| |
|
Effect of ergometric exercise on factor VIII coagulant activity in patients with mild and moderate hemophilia A
|
| Ravanbod R., Turkaman G., Baghaipoor M. R., NAD'Ali F. |
| |
|
Effect of etanercept on procoagulant activity and fibrinolysis in patients with rheumatoid arthritis
|
| Korzh I., Nemtsova V., Fedotova I., Korzh O. |
| |
|
Effect of extra virgin olive oil on experimental thrombosis and primary haemostasis in rats
|
| Brzosko S., De Curtis A., Murzilli S., Cerletti C., Donati M. B., De Gaetano G., Iacoviello L. |
| |
|
Effect of Fondaparinux on clot formation after tissue factor pathway activation. A thromboelastography study
|
| Chakroun T., Gerotziafas G. T., Elalamy I., Samama M. M. |
| |
|
Effect of heparin on thrombin generation in factor VIII depleted plasma supplemented with FEIBA or FVIII
|
| Parmar N., Berry L. R., Chan A. K. C. |
| |
|
Effect of hyperhomocysteinemia on coagulation activation and endothelial cell activation
|
| Gerdes V., ten cate H., Brandjes D. P. M., Macgillavry M. R., Leijte A., Reitsma P. H., Büller H. R. |
| |
|
Effect of hyperhomocysteinemia on paraoxonase activity
|
| Janel N., Robert K., Chabert C., Gouédard C., Demuth D., Quéré I., London J., Delabar J. M., Chassé J. F. |
| |
|
Effect of KFA-1982, a new orally active factor Xa inhibitor, in a rabbit venous thrombosis model
|
| Koizumi T., Nakano S., Hoyano Y., Kusama H., Kojima M., Shibata N. |
| |
|
Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix degrading enzyme aggrecanase: structure-function relationship
|
| Mousa S. |
| |
|
Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice
|
| Wilson K. M., Lynch C. M., Faraci F. M., Lentz S. R. |
| |
|
Effect of Mg(II) ion on the interaction of factor IX with phospholipid membrane
|
| Shikamoto Y., Morita T., Fujimoto Z., Mizuno H. |
| |
|
Effect of polymorphisms in the human TAFI 5'-flanking region on TAFI promoter activity
|
| Bastajian N., Nesheim M. E., Koschinsky M. L., Boffa M. B. |
| |
|
Effect of pravastatin on plasma markers of coagulation and inflammation in type 2 diabetes
|
| Sommeijer D. W., Mac Gillavry M. R., Meijers J. M. C., Reitsama P. H., Ten Cate H. |
| |
|
Effect of protein binding on the anti-FXa activity of different heparinoids in either adult or newborn plasma
|
| Paredes N., Berry L. R., Paes B., Chan A. K. C. |
| |
|
Effect of rFVIIa (NovSeven®) on thrombin generation in patients with severe thrombocytopenia
|
| Gerotziafas G., Depasse F., Drakopoulou A., Parashou S., Chakroun T., Zervas K., Arzoglou P., Elalamy I., Samama M. M. |
| |
|
Effect of short-term, low-fat vegetarian diet and walking program on coagulation
|
| Kehoe J., Gosselin R. C., Crane M., Emerson D., Mellgren S., Owings J. T. |
| |
|
Effect of simvastatin on the production of tissue-type plasminogen activator in endothelial cells
|
| Yang H., Fish R., Kruithof E. K. O. |
| |
|
Effect of the direct factor Xa inhibitor, DX-9065a, on thrombin generation in patients with stable coronary artery disease
|
| Alexander J. H., Becker R. C., Hasselblad V., Dyke C. K., Robertson T. L., Harrington R. A., Bovill E. G. |
| |
|
Effect of the LMWHs dalteparin and enoxaparin on tissue factor and thrombomodulin expression by endothelial cells
|
| Marchetti M., Vignoli A., Agosti M., Barbui T., Falanga A. |
| |
|
Effect of the methionine synthase reductase A66G polymorphism on total homocysteine levels and venous thrombosis risk
|
| Gellekink H., Kluijtmans L. A. J., Blom H. J., Van Lith-Zanders H., Den Heijer M. |
| |
|
Effect of type of treatment (recombinant vs. plasmatic) on FVIII inhibitor incidence according to known risk cofactors in previously untreated severe hemophilia A patients (Pups)
|
| Rothschild C., Goudemand J., Demiguel V., Lambert T., Calvez T. |
| |
|
Effect of warfarin anticoagulants on elements of the tissue factor pathway and other procoagulant markers
|
| Needham J., Mainwaring C. J., Knight S., Mclellan D. |
| |
|
Effectiveness of excluding pulmonary embolism in the elderly by using a clinical decision rule and d-dimer
|
| Van Mierlo P. J. W. B., Kamphuisen P. W., Söhne M., Jacobs E. M. G., Ullmann E. F., Büller H. R. |
| |
|
Effectiveness of polybrene neutralization of heparin and low-molecular weight heparin in plasma
|
| Messmore H. L., Fabbrini N. J., Coyne E., Balbale S., Crosby T., Love B., Iqbal O. |
| |
|
Effects of 6,7-dihydroxy-3-phenylcoumarin and warfarin on thromboplastin induced experimental disseminated intravascular coagulation
|
| Tunali T., Yarat A., Bulut M., Emekli N. |
| |
|
Effects of ADP-antagonists on platelet calcium mobilization in acute coronary syndrome patients
|
| Behan M., Fox S. C., Storey R. F., Heptinstall S. |
| |
|
Effects of adrenaline and noradrenaline on the expression of tissue factor in endothelial cells
|
| Xiong S. L., Wen Z. B., He X. F., Li X. F., He S. L. |
| |
|
Effects of age, sex, and oral contraceptive use on hemostatic, fibrinolytic and inflammatory variables: cross-sectional population survey
|
| Rumley A., Mcconnachie A., Upton M., O'Reilly D., Watt G., Lowe G. |
| |
|
Effects of anticoagulation, red blood cells and number of platelets on coagulation and clot elasticity measured by free oscillation rheometry
|
| Tynngård N., Lindahl T., Ramström S., Berlin G. |
| |
|
Effects of argatroban alone or in combination with phenprocoumon or acenocoumarol on aPTT and ecarin clotting time
|
| Harder S., Graff J., Osakabe M., Watanabe H., Breddin H. K. |
| |
|
Effects of argatroban in combination with oral anticoagulation on thrombin generation
|
| Harder S., Klinkhardt U., Osakabe M., Watanabe H., Breddin H. K. |
| |
|
Effects of bleeds on health-related quality of life in patients with hemophilia
|
| Fischer K., Van Dijk K., Van Der Bom J. G., Mauser-Bunschoten E. P., Roosendaal G., Van Den Berg H. M. |
| |
|
Effects of cardiopulmonary bypass on platelet activation markers
|
| Gonçalves L., Fraga M., Oliveira G., Castelo-Branco S., Pereira R., Cunha-Ribeiro L. M. |
| |
|
Effects of clopidogrel-aspirin combination vs. aspirin alone on platelet aggregation and major receptor expression in patients with heart failure. For the plavix use for treatment of congestive heart failure (PLUTO-CHF) trial
|
| Serebruany V., Malinin A., Jerome S., Lowry D., Sane D. |
| |
|
Effects of CS-747, a novel P2Y12 receptor antagonist, on cerebral and peripheral arterial occlusive diseases in rats
|
| Asai F., Niitsu Y., Ogawa T., Otsuguro K., Nagasawa T., Nakanishi Y., Tani Y., Murakami Y., Sugidachi A. |
| |
|
Effects of dietary fish oil on coagulation and platelets
|
| Vanschoonbeek K., Feijge M. A. H., Paquay M., De Maat M. P., Heemskerk J. W. M. |
| |
|
Effects of different heparins on thrombin-activatable fibrinolysis Inhibitor-TAFI in hemodialyzed patients
|
| Malyszko J., Mysliwiec M. |
| |
|
Effects of enoxaparin on high glucose induced activation of human endothelial cells
|
| Manduteanu I., Antohe F., Dragomir E., Voinea M., Capraru M., Radulescu L., Simionescu M. |
| |
|
Effects of factor VIII (fVIII) levels and activated partial thromboplastin time (aPTT) in activated protein C resistance (APC-R) ratio using two different methods
|
| Grosso S. H., Gennari L. C., Salviu M. J., Nadal M. V., Blanco A. N., Lazzari M. A. |
| |
|
Effects of Factor Xa and protein S on the individual APC-cleavage sites of factor Va
|
| Norstrøm E., Steen M., Dahlbäck B. |
| |
|
Effects of fluvastatin on up-regulation of tissue factor by antiphospholipid antibodies
|
| Pierangeli S., Ferrara D. E., Harris E. N., Swerlick R. |
| |
|
Effects of full and partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II on the inhibition of thrombin and activated protein C
|
| Filion M. L., Bhakta V., Nguyen L. H., Liaw P. S., Sheffield W. P. |
| |
|
Effects of genes and environmental factors on homocysteine level
|
| Den Heijer M., Graafsma S., Van Landeghem A. A. J., Blom H. J. |
| |
|
Effects of HRT with estradiolvalerate 2-mg + levonorgestrel 75 µg (NUVELLE®) on clotting and lipid profile
|
| Falciani M., Beninato L., Bruni V., Checcucci V., Pampaloni F., Cellai A. P., Scarselli G., Abbate R., Fedi S., Bucciantini M. S. |
| |
|
Effects of isolated and combined use of ticlopidine, clopidogrel and aspirin on platelet function as evaluated by platelet aggregometry
|
| Villela M. S. H., Martins E. C. S., Matos M. F., Colangello L. M., Franco R. F., Figueiredo M. S. |
| |
|
Effects of platelet agonists and antiplatelet agents on thrombin formation in human plasma
|
| Vanschoonbeek K., Feijge M. A. H., Van Kampen R., Hemker H. C., Giesen P., Heemskerk J. W. M. |
| |
|
Effects of proteasome inhibitors on alpha-granule secretion and microparticle formation during thrombin-induced platelet activation
|
| Ostrowska H., Manur M., Ostrowska J. K. |
| |
|
Effects of protein S and phospholipid on individual APC-cleavage sites in factor Va
|
| Norstrøm E., Dahlbäck B. |
| |
|
Effects of simvastatin on secretagogue-induced exocytosis from endothelial cells
|
| Yang H., Kruithof E. K. O. |
| |
|
Effects of statins on adhesion molecules expression in endothelial cells
|
| Dimitrova Y., Dunoyer-Geindre S., Kruithof E., Reber G., Mach F., De Moerloose P. |
| |
|
Effects of strong static magnetic fields on fibrinolysis
|
| Higashi T. |
| |
|
Effects of three low doses of aspirin on thromboxane synthesis in platelets and on bleeding time – a comparative study
|
| Svensson J., Elwin C.-E. |
| |
|
Efficacy and safety of low dose vitamin K in outpatient management of patients with an INR > 10
|
| Gunther K. E., Conway G., Leibach L. |
| |
|
Efficacy and safety of once-daily Enoxaparin given in the outpatient setting compared with in-hospital unfractionated heparin for treatment of proximal lower limb deep-vein thrombosis
|
| Ramacciotti E., Araújo G. R., Lastoria S., Maffei F. H., Dietrich-Neto F., CLETRAT INVESTIGATORS¶ |
| |
|
Efficacy and safety of the first nanofiltered plasma-derived FVIII (FACTANE®) in previously treated haemophilia A patients
|
| Rothschild C., Goudemand J., Alcalay M., Stieltjes N., Chambost H., Dirat G., Laubriat M., Duboullay C., Négrier C., Borel-Derlon A., Bridey F. |
| |
|
Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study
|
| Huisman M.V., on behalf of The THRIVE Treatment Study Inv, Netherlands |
| |
|
Efficacy and safety of the treatment regimen of melagatran and ximelagatran for prevention of thromboembolic events after total hip or knee replacement: a meta-analysis of 3 randomized, double-blind studies, to evaluate the influence of time and dose
|
| Cohen A. T., Agnelli G., Dahl O. E., Eriksson B. I., Kälebo P., Lassen M. R., Mouret P., Rosencher N., Andersson M., Eskilson C., Panfilov S. |
| |
|
Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study
|
| Brenner B., Hoffman R., Carp H., Dulitsky M., Samueloff A., Yohal D., Bar Y., Thaler I., Yarom I., Ellis M., Varon D., Tal Y., Blumenfeld Z., Segal S., Kupferminc M., Younis J., LIVE-ENOX INVESTIGATORS |
| |
|
Efficacy and safety profile of rAHF-PFM in the surgery setting
|
| Negrier C. |
| |
|
Efficacy of 1-year acenocumarol therapy and its relation with gene polymorphism related to thrombophilia in patients with nonvalvular atrial fibrillation
|
| Kropacheva E., Panchenko E., Dobrovolsky A., Ataullahanova D., Titaeva E., Zharkova T., Kovalenko T., Suhoverhova A., Patrusheva N., Patrushev L. |
| |
|
Efficacy of fondaparinux (Arixtra) in extended thromboprophylaxis in hip fracture surgery is irrespective of patient and surgical characteristics: subgroup analyses of the Penthifra-Plus study
|
| Lassen M. R., Eriksson B. I. |
| |
|
Efficacy of Haemate P in the management of patients with von Willebrand disease undergoing surgery
|
| Rossetti G., Franchini M., Tagliaferri A., Bertuzzo D., Pattacini C., De Gironcoli M., Gandini G. |
| |
|
Efficacy of high purity, monoclonal factor IX concentrate for continuous infusion in an hemophilia B patient undergoing orthopedic surgery
|
| Barillari G., Turello M., Croppo C., Croppo C., Causero A., Biffoni F. |
| |
|
Efficient human thrombin generation requires molecular phosphatidylserine and not a membrane surface
|
| Majumder R., Weinreb G. E., Lentz B. R. |
| |
|
Eight-year follow-up of a randomized trial investigating vena cava filters in the prevention of PE in patients presenting a proximal DVT: The PREPIC trial
|
| Decousus H. |
| |
|
Electron microscopy of thrombasthenic platelets after rFVIIa substitution
|
| Westrup D., Bassus S., Kirchmaier C. M., Morgenstern E. |
| |
|
Elevated coagulation factors in rabbits (Oryctolagus cunniculus) following brown recluse envenomation (Loxoceles reclusa)
|
| Mcglasson D., Harroff H. H., Dick E., Sutton J. |
| |
|
Elevated concentrations of nitrate in plasma from smokers
|
| Mansoor M., Kristensen O., Hervig T., Stakkestad A., Berge T., Drabløs P. A., Rolfsen S. |
| |
|
Elevated factor VIII: a possible link between periodontal disease and acute coronary syndrome
|
| Das Gupta A., Syed K., Sethi M., Chandan K., Ponde C. K., Rajani R., Kumar N., Bajan K., Kamble P., Pol D. |
| |
|
Elevated factor VIIIC and further prothrombotic risk factors in paediatric venous thrombosis and stroke: a multivariate analysis
|
| Nowak-Goettl U., Schulte T., Kurnik K., Heller C. H., Schobess R., Junker R. |
| |
|
Elevated factor VIIIC level is a major risk factor for venous thrombo-embolism in the black population
|
| Patel R. K., Ford E., Bonner L., Thumpston J., Arya R. |
| |
|
Elevated levels of d-dimer and fragment 1 + 2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis
|
| Jansen F. H., Van Der Straaten H. M., Roest M., Haas F., De Groot P. H. G., Fijnheer R. |
| |
|
Elevated plasma cysteine concentration as a risk factor for venous thrombosis
|
| Blom H. J., Bos G. M. J., Rosendaal F. R., Den Heijer M., Keijzer M. B. A. J. |
| |
|
Elevated plasma factor XIII relates to intima media thickness of carotid arteries in primary antiphospholipid syndrome
|
| Ames P. R. J., Margarita A., Delgado-Alves J., Iannaccone L., Brancaccio V. |
| |
|
Elevated plasma levels of factor VIII in women with early recurrent miscarriage
|
| Marietta M., Facchinetti F., Blasi I., Fazzio M., Bertesi M., Cappi C., Pozzi S., Torelli G. |
| |
|
Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with DIC
|
| Matsumoto T., Wada H., Sase T., Nobori T., Shiku H., Sawai T., Nagahama Y., Tanaka H., Matsuda M. |
| |
|
Elevated Serum Nerve Growth Factor (NGF) levels in patients with acute leukemia and lymphoma especially with CNS involvement
|
| Elbaz O., Mansour A., Fouda M., Abo Elfetoh N. |
| |
|
Elevated soluble thrombomodulin levels in patients with acute coronary syndrome: down-regulation by anticoagulant dosage of low molecular weight heparins
|
| Hoppensteadt D., Florian-Kujawski M. R., Leya F., Kereiakes D. J., Lewis B., Fareed J. |
| |
|
Elevated steady state serum sVCAM-1 levels occur from an early age in sickle cell patients, but are not related to vasoocclusive crises and acute chest syndrome frequency
|
| Schnog J., Brandjes D., Rojer R., Mac Gillavry M., Ten Cate H., Duits A. |
| |
|
Eleven novel mutations in non-Jewish factor XI deficient kindreds detected by SSCP with heteroduplex analysis followed by sequencing
|
| Bolton-Maggs P., Butler R., Mountford R., Gailani D. |
| |
|
Embryo implantation after assisted reproductive procedures and maternal thrombophilia
|
| Martinelli I., Passamonti S. M., Battaglioli T., Taioli E., Ragni G., Levi-Setti P., Lodigiani C., Mannucci P. M. |
| |
|
Emerging prognostic factors in ischemic heart disease
|
| Brogi D., Sofi F., Marcucci R., Fedi S., Cellai A. P., Gensini F., Sestini I., Giuello A., Gazzini A., Abbate R., Gensini G. F. |
| |
|
Emotional impact of testing for inherited thrombophilia
|
| Legnani C., Razzaboni E., Gremigni P., Ricci Bitti P. E., Palareti G. |
| |
|
Encrypted tissue factor (TF) in circulating human monocytes of healthy individuals
|
| Breimo E., Olsen J. O., Østerud B. |
| |
|
Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool
|
| Thomassen M., Castoldi E., Tans G., Magdeleyns E. J. P., Delaunoit C., Debusscher L., Van Assche K. W. A., Rosing J. |
| |
|
Endothelial and angiogenesis activity in terminal heart failure and heart-transplant patients: a prospective study
|
| Martínez-Sales V., Reganon E., Vila V., Martin J., Villa V., Aznar J., Almenar L. |
| |
|
Endothelial anticoagulant thrombomodulin (TM) as a natural anti-inflammatory, ‘HMG1 blocker’, inhibits pro-inflammatory cell activation
|
| Abeyama K., Kawahara K., Yamaji K., Maruyama I. |
| |
|
Endothelial cell and monocyte-derived microparticles in severe dengue virus infections
|
| Mairuhu A. T. A., Leyte A., Setiati T. E., Djamiatun K., Sturk A., Soemantri A. G., Ten Cate H., Nieuwland R., Van Gorp E. C. M., Brandjes D. P. M. |
| |
|
Endothelial cell damage as shown by raised soluble-thrombomodulin and total von Willebrand factor antigen levels during heparin induced thrombocytopenia
|
| Davidson S. J., Burman J. F. |
| |
|
Endothelial cells cocultured with monocytes are activated to support the adhesion of flowing leukocytes by a combination of TNF-a IFN-g and TGF-b1, a process that is progressively ablated as monocytes differentiate into macrophages
|
| Tsouknos A., Nash G. B., Rainger G. E. |
| |
|
Endothelial damage in congestive heart failure (CHF): relationship between circulating endothelial cells (CECs) and von Willebrand factor (vWf)
|
| Chong A., Blann A., Lip G. Y. H., Freestone B. |
| |
|
Endothelial nitric oxide synthase gene variation and hypertension in pregnancy
|
| Grandone E., Colaizzo D., Martinelli P., Vecchione G., Pavone G., Errico M., Margaglione M. |
| |
|
Endothelial protein C receptor (EPCR) is expressed in placental villi and cultured syncytiotrophoblasts
|
| Lanir N., Aharon A., Khamaysi I., Fukudome K., Brenner B. |
| |
|
Endothelial-specific inactivation of survivin in mice results in embryonic lethality with intraembryonic bleeding due to loss of vascular endothelial integrity
|
| Zwerts F., DeVriese A., Pollefety S., Collen D., Conway E. M. |
| |
|
Enhanced in vivo platelet activation in patients with peripheral arterial disease, and differences between intermittent claudication and critical limb ischemia
|
| Ford I., Cassar K., Mitchell L., Greaves M., Bachoo P., Brittenden J. |
| |
|
Enhanced anti-angiogenesis ability of human kringle 1–5 domain via altering glycosylation sites and lysine binding properties
|
| Chang Y. J., Lin C. I., Chang C. W., Su Y. T., Wu H. L., Shi G. Y. |
| |
|
Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus
|
| Hu H., Yngen M., Daleskog M., Johansson M., Wallén N. H., Li N., Hjemdahl P. |
| |
|
Enhanced platelet and leukocyte activation by strenuous exercise in type I diabetes mellitus
|
| Hu H., Yngen M., Daleskog M., Johansson M., Wallén N. H., Li N., Hjemdahl P. |
| |
|
Enhanced procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in plasma from patients with severe haemophilia A
|
| Lisman T., De Groot P. G., Lambert T., Rojkjaer R., Persson E. |
| |
|
Enhanced sensitivity to thrombin but not thrombin activation peptides in female mouse platelets is induced by low dose estrogen unrelated to ER
|
| Bray P. |
| |
|
Enhanced thrombin generation and mild bleeding tendency in a severely FVII-deficient patient carrying FV Leiden
|
| Castoldi E., Govers-Riemslag J. W. P., Bindini D., Pinotti M., Tans G., Berrettini M., Mazzucconi M. G., Bernardi F., Rosing J. |
| |
|
Enhanced thrombus recanalization and resolution after vascular endothelial growth factor (VEGF) naked DNA gene transfer
|
| Waltham M., Fenske C., Burnand K., Carter N., Smith A. |
| |
|
Enhanced TNF-a and oxidative stress in patients with heart failure: effect of TNF-a on platelet O2 production
|
| Pignatelli P., De Biase L., Lenti L., Tocci G., Piccioni F., Riondino S., Pulcinelli F. M., Rubattu S., Volpe S., Violi F. |
| |
|
Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting factor Xa, but not by those inhibiting thrombin or tissue factor
|
| Lisman T., Adelmeijer J., Nieuwenhuis H. K., De Groot P. G. |
| |
|
Enhancing hemophilia care and patient adherence using Advoy.com
|
| Valention L. A. |
| |
|
Eosinophils as a novel target for protein C
|
| Feistritzer C., Sturn D. H., Kaneider N. C., Wiedermann C. J. |
| |
|
EPC restoration of cardio protection for the aging heart
|
| Edelberg J. |
| |
|
Epidemiology of inherited thrombophilia in Slovakia
|
| Kubisz P., Ivanková J., Stasko J. |
| |
|
Epidemiology of postoperative venous thromboembolism in Asian countries: results of the SMART study
|
| Leizorovicz A. |
| |
|
Epidermiology and anti-inflammatory mechanism - Differential diagnosis of thrombotic conditions
|
| Pabinger I. |
| |
|
Epidermiology and anti-inflammatory mechanism - Epidemiology and pharmacoeconomics
|
| Watson S. |
| |
|
Epidermiology and anti-inflammatory mechanism - Latest insight in anti-inflammatory mechanisms
|
| Hack E. |
| |
|
Epinephrine promotes LPS-induced interleukin-8 (IL-8) production in whole blood through thromboxane A2
|
| Østerud B., Lund T. |
| |
|
Epitopes of factor VIII inhibitors analyzed by peptide-arrays
|
| Albert T., Brackman H. H., Graw J., Oldenburg J., Schramm W., Schwabb R. |
| |
|
Equilibrium binding measurements of the exosite-dependent interactions of substrates or product with the prothrombinase complex
|
| Boskovic D., Krishnaswamy S. |
| |
|
Equivalence of venous and capillary INR values determined with the new CoaguChek® PT.S-test on the CoaguChek® S system
|
| Plesch W., Klimpel P., Miller E., Fuller J., Newhart A., Jacobson A., Gutnik L. |
| |
|
Erythrocytes bearing (carboxymethyl)lysine bind to endothelial RAGE and alter vascular permeability in diabetic rats
|
| Wautier J. L., Wautier M. P. |
| |
|
Erythrocytes from diabetic patients adhere to endothelium and potentiate leukocyte adhesion molecule expression
|
| Wautier M. P., Boulanger E., Wautier J. L. |
| |
|
Erythrocytic membrane proteins in sickle cell anemia in crisis and steady state
|
| Kilinc Y., Askoy K., Yuzbasioglu S., Kozanoglu H. H., Sezgin Y., Yalin S., Alpaslan N. |
| |
|
Establishing links between coagulation and inflammation: The lectin-like domain of thrombomodulin confers protection in a murine model of rheumatoid arthritis
|
| Van De Wouwer M., Clijsters K., Plaisance S., Collen D., Conway E. M. |
| |
|
Establishment of urokinase receptor gene antisense RNA transfer system and its influence on uPAR expression in leukemia cells
|
| Bai X., Fu J., Xi X., Wang Z., Ruan C. |
| |
|
Estimation of plasminogen activator inhibitor type 1 (PAI-1) and plasmin-alpha-2-antiplasmin complex (PAP) serum activities in personal computers operators
|
| Kazmierska E., Swiatkowska-Stodulska R., Czestochowska E. |
| |
|
Estimation of von Willebrand factor: collagen binding in therapeutic concentrates
|
| Hubbard A., Weller L. J. |
| |
|
Estrogens, progestogens and thrombosis
|
| Rosendaal F. R., Van Hylckama Vlieg A., Tanis B. C., Helmerhorst F. M. |
| |
|
Ethnic differences in the frequencies of polymorphisms of protein S and protein C in South African populations
|
| Nel M. J., Gaillard M.-C., Thomson P. D. |
| |
|
European action on anti-coagulation – cost effectiveness of computer assisted anti-coagulant dosage
|
| Poller L., Jespersen J., Tripodi A., Van Den Besselaar A. M. H. P., Van Der Meer F. J. M., Shiach C., Keown M., Bryan S. |
| |
|
European concerted action on anti-coagulation (ECAA). Correction of displayed INR on two point-of-care test (POCT) whole blood prothrombin time monitors (CoaguChek Mini and TAS PT-NC) by independent International Sensitivity Index (ISI) calibration
|
| Poller L., Keown M., Chauhan N., Van Den Besselaar A. M. H. P., Tripodi A., Shiach C., Jespersen J. |
| |
|
European concerted action on anti-coagulation (ECAA). reliability of International Normalized Ratios (INR) from CoaguChek mini and TAS PT-NC whole blood point-of-care test monitor systems
|
| Keown M., Poller L., Chauhan N., Van Den Besselaar A. M. H. P., Tripodi A., Shiach C., Jespersen J. |
| |
|
European forum on antiphospholipid antibodies standardization group: results of the 2nd round on antibeta2glycoprotein I home-made assays
|
| Reber G., Sanmarco M., Tincani A., Boffa M. C., De Moerloose P. H., Arvieux J. |
| |
|
Evaluating 'aspirin resistance' in a population with cardiovascular disease
|
| Maree A., Curtin R., Dooley M., Crean P., Fitzgerald D. J. |
| |
|
Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review
|
| Raskob G., Kearon C., Geerts W., Planes A., Eriksson B., Paiement G., Lassen M., Bergqvist D., Turpie G., Agnelli G., Buller H., Hirsh J. |
| |
|
Evaluating the interaction of allopurinol with the oral anticoagulants
|
| Rodrigues I., Martins R., Viegas E. |
| |
|
Evaluation of a ‘handheld’ communicator based electronic system for documentation of hemophilia A and B therapy in home-care settings
|
| Mondorf W., Pollmann H., Hense M. |
| |
|
Evaluation of a bed-side device to assess the APTT for heparin monitoring in infants
|
| Burggraaf J., Rienstra M. E., De Wilde R. B. P., Hogenbirk K., Gosselaar C., Van Der Vorst M. M. J. |
| |
|
Evaluation of a clinical algorithm in nurse led DVT management to identify underlying malignancy
|
| Rhodes S., Bond S., Bradbury M., Rose P. |
| |
|
Evaluation of a new quantitative, rapid test (VWF-LIA) for the diagnosis of type 1 VWD
|
| Tosetto A., Castaman G., Rodeghiero F., Peake I. R., Goodeve A., Federici A. B., Battle J., Meyer D., Eikenboom J. C. M., Schneppenheim R., Ingerslev J., Vorlova Z., Lethagen S., Pasi J., Hill F. |
| |
|
Evaluation of a protein truncation test (PTT) for mutation detection in von Willebrand disease
|
| Lester W. A., Surdhar G. K., Guilliatt A. M., Enayat M. S., Hill F. G. H. |
| |
|
Evaluation of a venous-return assist device (venowave) to treat post-thrombotic syndrome: a phase II study
|
| O'Donnell M., Ginsberg J. S., Saringer J., Kearon C., Magier D., Hirsh J. |
| |
|
Evaluation of an automated assay for rapid analysis of von Willebrand ristocetin cofactor activity
|
| Strandberg K., Andersson K., Carlson M., Lethagen S., Hillarp A. |
| |
|
Evaluation of an automated von Willebrand factor (vWF) antigen assay
|
| Kretschmer V., Weippert-Kretschmer M., De Groot F., Merz M., Engel Hardt W. |
| |
|
Evaluation of aspirin resistance by platelet function analyzer (PFA-100™) in patients with acute coronary syndrome®
|
| Camoin-Jau L., Barragan P., Laibbe S., Dignat-George F., Sampol J. |
| |
|
Evaluation of automated measurement of ristocetin cofactor activity of von Willebrand factor on STA-R® in von willebrand disease: study in 154 patients
|
| Trossaert M., Caron C., Barat N., Nicham F., Goudemand J., Fressinaud E. |
| |
|
Evaluation of HaemosIL HS-CRP. A new latex immunoassay to quantitatively determine C-Reactive Protein (CRP) in citrated plasma, totally automated on coagulation analysers
|
| Serra J., Sánchez T., Canaleta C., Ars E. |
| |
|
Evaluation of IgG formation to trace mammalian proteins in hemophilia patients treated with a recombinant therapeutic protein preparation
|
| Gorina E., Zhang C., Larson P., Burmeister Getz E. |
| |
|
Evaluation of platelet function analyzer (PFA-100), whole blood (WB), and platelet rich plasma (PRP) aggregation methods in detecting aspirin resistance
|
| Dyszkiewicz-Korpanty A., Sarode R., Yassin J., Frenkel E. P. |
| |
|
Evaluation of protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) plasma levels and the in vitro inhibition of activated factor X by PZ/ZPI in patients with autoimmune aPL
|
| Forastiero R., Martinuzzo M., Lu L., Broze Jr G. J. |
| |
|
Evaluation of rAHF-PFM in pediatric and previously untreated patients
|
| Blanchette V. |
| |
|
Evaluation of rAHF-PFM in previously treated patients
|
| Tarantino M. |
| |
|
Evaluation of skeletal muscle perfusion in a hindlimb ischemia model using 99 mTc-sestamibi scintigraphy
|
| Paula E. V., Ramos C. D., Garcia R. A., Guillaumon A. T., Annichino-Bizzacchi J. M. |
| |
|
Evaluation of the fibrinolytic capacity before and after venous occlusion performed by serum d-dimer test after standardized coagulation
|
| Paniccia R., Bandinelli B, Attanasio M., Rossi L., Lari B., Lombardi A., Falciani M., Gori A.M., Abbate R., Prisco D. |
| |
|
Evaluation of the point of care Helena ICHOR/Plateletworks® and the Accumetrics Ultegra® RPFA for assessment of platelet function inhibition by platelet GPIIb-IIIa antagonists
|
| Jennings L., White M. M., Jacoski M. V., Krishna R. |
| |
|
Evaluation of the rFVIIa efficacy in children's haemorrhages of different etiology
|
| Serban M., Petrescu C. A. M., Jinca C., Mihailov D. |
| |
|
Evaluation of the role of genetic analysis in dysfibrinogenemia
|
| Hill M., Harrison S. J., Strong J., Tait R. C., Dolan G. |
| |
|
Evaluation of the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic approach to determine Glanzmann Thrombasthenia in blood platelet lysates
|
| Van Heerde W., Loof A., Novakova I. R. O., Mensink E., Verbruggen H. |
| |
|
Evidence for a functional role of 5-hydroxytryptamine-2 A receptor gene (HTR2A) polymorphism (T102C) in human platelet aggregation
|
| Ozdener F., Gulbas Z., Ozdemir V. |
| |
|
Evidence for a functionally active protease-activated receptor-3 in human vascular smooth muscle cells
|
| Bretschneider E., Spanbroek R., Loetzer K., Habenicht A., Schroer K. |
| |
|
Evidence for a PLCg2-independent alpha2beta1-triggered signalling pathway contributing to platelet aggregation in response to collagen
|
| Mangin P., Nonne C., Eckly A., Freund M., Cazenave J.-P., Gachet C., Lanza F. |
| |
|
Evidence for a role of tachykinins in the regulation of human platelet activation
|
| Graham G., Thomas J. M., Page N. M., Lowry P. J., Gibbins J. M. |
| |
|
Evidence for a serum protein mediating Staphylococcus aureus induced platelet aggregation
|
| Brennan M., Foster T. J., Cox D. |
| |
|
Evidence for extracellular signal-regulated kinase 1/2 activation by thrombin that is independent on epidermal growth factor receptor transactivation in vascular smooth muscle cells
|
| Bobe R., Yin X., Roussanne M. C., Stepien O., Polidano E., Faverdin C., Marche P. |
| |
|
Evidence of C677T methylentetrahydrofolate reductase (‘MTHFR’) and hyperhomocysteinemia (HH) – causal or casual coexisting risk factors?
|
| Ames M., Stephan B., Ihle A., Seyfert U. T., Schenk J. F. |
| |
|
Evidence of transient endothelial activation in patients in sinus rhythm after electrical cardioversion of persistent atrial fibrillation
|
| Hogg D., Ford I., Booth N. A., Cowie M., Greaves M. |
| |
|
Evidence supporting a functional role for the metal binding site observed within the protease domain of Factor IXa
|
| Goodwin C. A., Kakkar V. V., Scully M. F. |
| |
|
Evidence that interaction of the A2 domain of factor VIIIa with factor IXa occurs over an extended surface
|
| Jenkins P. V., Dill J. L., Zhou Q., Fay P. J. |
| |
|
Evolution of a nonocclusive deep vein thrombosis in the rabbit vena cava
|
| Vallez M. O., Rupin A., Verbeuren T. J. |
| |
|
Examining the role of coagulation Factor VII using FVII-insufficient mice
|
| Rosen E., Liang Z., Zollman A., Roahrig J., Castellino F. J. |
| |
|
Excretion of the oral direct thrombin inhibitor ximelagatran into breast milk following oral administration to breast-feeding women
|
| Hellegren M., Johansson S., Eriksson U. G., Wåhlander K. |
| |
|
Experience of using FEIBA™ to attenuate the effects of anticoagulation on inhibition of thrombogenesis in primates
|
| Gruber A., Kotzé H., Carlsson S., Sarich T., Marzec U., Hanson S. |
| |
|
Experimental studies of anorectic drug cardiovascular toxicity: oral fenfluramine decreases dog platelet serotonin uptake and content, elevates plasma serotonin and causes mild mitral valve regurgitation
|
| Johnson G. J., Leis L. A., Murar J., Weir E. K. |
| |
|
Exposure of a binding site for the low-density lipoprotein receptor-related protein (LRP) upon activation of factor V
|
| Bos M. H. A., Bovenschen N., Boertjes R. C., Van Der Zwaan C., Van Rhenen K., Hilkes Y. H. A., Meijer A. B., Mertens K. |
| |
|
Exposure of procoagulant phospholipids in blood during exhaustive physical exercise
|
| Wagenvoord R., De Smedt E., Kai H., Béguin S., Hemker H. C. |
| |
|
Expression and function of platelet glycoproteins in newborns and adults
|
| Carlsson L., GroßJohann B., Hartmann W., Lehnigk U., Volgmann T., Frank J., Greinacher A. |
| |
|
Expression of a new candidate mutation, G1629R, identified in an Italian patient with type 2A von Willebrand disease
|
| Hilbert L., Federici A. B., Baronciani L., Mazurier C. |
| |
|
Expression of endothelial protein C receptor by human neutrophils and its role in cell migration
|
| Sturn D. H., Kaneider N. C., Feistritzer C., Djanani A., Wiedermann C. J. |
| |
|
Expression of full-length recombinant factor VIII by doxycycline-controlled expression system
|
| Huang C. C., Hsu Y. C., Lin S. W. |
| |
|
Expression of human tissue factor pathway inhibitor and hirudin fusion proteins on mouse vascular smooth muscle cells inhibits vascular remodeling after wire-induced carotid artery injury
|
| Chen D., Kemball-Cook G., Mcvey J., Tuddenham E. G., Lechler R. I., Dorling A. |
| |
|
Expression of Plasminogen activator inhibitor-1 (PAI-1) mRNA in human ciliary processes and determination of PAI-1 in human aqueous humor
|
| Wilhelm C., Meyer M. W., Von Depka M., Czwalinna A., Schroeder A., Erb C. |
| |
|
Expression of prion protein (PrPC) in the megakaryocyte lineage
|
| Starke R., Harrison P., Wang G., Erusalimsky J., Pizzey A., Mackie I., Machin S. |
| |
|
Expression of recombinant human gla-domainless factor X (gdFX) in the baculovirus: assessing substrate recognition by the intrinsic tenase complex
|
| Yuan Q. P., Annis D. S., Kirkpatrick H. M., Mosher D. F., Sheehan J. P. |
| |
|
Expression of wild type tissue factor pathway inhibitor (TFPI) and the first natural TFPI mutant ([P151L]) in insect and mammalian cells
|
| Thyzel E., Siegling S., Götting C., Brinkmann T., Kleesiek K. |
| |
|
Expression pattern and intracellular localization of the A subunit for coagulation factor XIII
|
| Souri M., Ichinose A. |
| |
|
Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial
|
| Eriksson H., Wahlander K., Lundström T., Billing Clason S., Schulman S., Thrive III Investigators |
| |
|
Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study
|
| Hull R., Schellong S., Tapson V., Yusen R., Monreal M., Samama M. M., Turpie A. G. G., Wildgoose P., Cort S. |
| |
|
Extending standards of care to medical patient
|
| Cohen A. |
| |
|
Extension of human platelet storage up to 7–8 days does not reduce their in vivo viability in a rabbit model
|
| Leytin V., Allen D. J., Hannach B., Freedman J. |
| |
|
Extracorporeal adsorption of Factor VIII antibodies on randomly functionalized polystyrene resins
|
| Huguet H., Lasne D., Rothschild C., Siali R., Jozefonvicz J. |
| |
|
Extracorporeal adsorption of Factor VIII antibodies on randomly functionnalised polystyrene resins
|
|
| |
|
Extrahepatic synthesis of coagulation factor VII in prostate and breast cancer
|
| Wilcox J., Jaye D. L., Joseph G., Casanova J. R. |
| |
|
Extrinsic pathway function, thrombin generation potential and perioperative blood loss in CABG surgery
|
| Gruenewald M., Siegemund A., Goedjs O., Gallmeier G. U., Stiller P., Gruenewald A., Konegen A., Griesshammer M. |
| |
